Listar por autor "Yee, James P."

Mostrando ítems 1-3 de 3

    • Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II 

      Crespo-Leiro, María Generosa; Stypmann, Jörg; Schulz, Uwe; Zuckermann, Andreas; Mohascsi, Paul; Bara, Christian; Ross, Heather; Parameshwar, Jayan; Zakliczynski, Michal; Fiocchi, Roberto; Hoefer, Daniel; Colvin, Monica; Deng, Mario; Leprince, Pascal; Elashoff, Barbara; Yee, James P.; Vanhaecke, Johan (Oxford University Press en nombre de European Society of Cardiology, 2016-01-07)
      [Abstract] Aims. A non-invasive gene-expression profiling (GEP) test for rejection surveillance of heart transplant recipients originated in the USA. A European-based study, Cardiac Allograft Rejection Gene Expression ...

    • Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients 

      Crespo-Leiro, María Generosa; Stypmann, Jörg; Schulz, Uwe; Zuckermann, Andreas; Mohacsi, Paul; Bara, Christoph; Ross, Heather; Parameshwar, Jayan; Zakliczynski, Michal; Fiocchi, Roberto; Hoefer, Daniel; Deng, Mario; Leprince, Pascal; Hiller, David; Eubank, Emir; Yee, James P.; Vanhaecke, Johan (BioMed Central, 2015-10-09)
      [Abstract] Background. A single non-invasive gene expression profiling (GEP) test (AlloMap®) is often used to discriminate if a heart transplant recipient is at a low risk of acute cellular rejection at time of testing. ...

    • Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients 

      Grskovic, Marica; Hiller, David J.; Eubank, Lane A.; Sninsky, John J.; Christopherson, Cindy; Collins, John P.; Thompson, Kathryn; Song, Mindy; Wang, Yue S.; Ross, David; Nelles, Mitchell J.; Yee, James P.; Wilber, Judith C.; Crespo-Leiro, María Generosa; Scott, Susan L.; Woodward, Robert N. (Elsevier para American Society for Investigative Pathology and the Association for Molecular Pathology, 2016-10-07)
      [Abstract] The use of circulating cell-free DNA (cfDNA) as a biomarker in transplant recipients offers advantages over invasive tissue biopsy as a quantitative measure for detection of transplant rejection and immunosuppression ...